Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study.

Milosevic, Michael F

Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study. [electronic resource] - International journal of radiation oncology, biology, physics Jan 2016 - 111-117 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

1879-355X

10.1016/j.ijrobp.2015.09.009 doi


Angiogenesis Inhibitors--administration & dosage
Antineoplastic Agents--administration & dosage
Biomarkers
Brachytherapy--methods
Carcinoma, Squamous Cell--blood supply
Cell Hypoxia
Chemoradiotherapy--methods
Cisplatin--administration & dosage
Drug Administration Schedule
Early Termination of Clinical Trials
Female
Follow-Up Studies
Humans
Niacinamide--administration & dosage
Oxygen--metabolism
Partial Pressure
Phenylurea Compounds--administration & dosage
Radiation Tolerance--drug effects
Sorafenib
Time Factors
Tumor Burden
Uterine Cervical Neoplasms--blood supply